Harrow completes NDA transfer of Vigamox, launches product in US
Click Here to Manage Email Alerts
Harrow announced it will begin marketing and selling Vigamox, a fluoroquinolone antibiotic eye drop for bacterial conjunctivitis, following completion of the product’s new drug application transfer.
According to a company press release, Harrow in January purchased exclusive U.S. commercial rights to Vigamox (moxifloxacin hydrochloride ophthalmic solution 0.5%), along with four other FDA-approved ophthalmic products, for $130 million.
“With an exceptional record of safety and efficacy, Vigamox is a well-known, reliable and trusted product by U.S. eye care professionals, many of whom regard Vigamox as the preferred broad-spectrum topical antibiotic to treat patients for bacterial conjunctivitis, as well as many other common bacterial-based infections,” Mark L. Baum, CEO of Harrow, said in the release.
The eye drop is indicated for treatment of bacterial conjunctivitis caused by susceptible staphylococci, streptococcal and haemophili strains, among others, the company stated.
“Having now completed the NDA transfer of Vigamox, we are excited to begin the implementation of the market access, marketing, inventory management, national sales detailing and other brand-leveraging strategies that we have developed during this transfer period,” Baum said.
Reference:
- Harrow closes acquisition of U.S. rights to Ilevro, Nevanac, Vigamox, Maxidex and Triesence and will begin receiving net profit payments for acquired products. https://investors.harrow.com/news-releases/news-release-details/harrow-closes-acquisition-us-rights-ilevror-nevanacr-vigamoxr. Published Jan. 23, 2023.
Read more about
Click Here to Manage Email Alerts